EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG

Florus C de Jong, Vebjørn Kvikstad, Robert F Hoedemaeker, Angelique C J van der Made, Thierry P van der Bosch, Niels J van Casteren, Kim E M van Kessel, Ellen C Zwarthoff, Joost L Boormans, Tahlita C M Zuiverloon

World Journal of Urology · 2025

DOI: 10.1007/s00345-024-05392-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Urology, 2025. Verfasst von Florus C de Jong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Ne…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, B7-H1 Antigen, BCG Vaccine, Biomarkers, Tumor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erasmus Universitair Medisch Centrum Rotterdam.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk of progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects of BCG are driven by a cytotoxic T cell response, which may be controlled by immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1). Here, we hypothesized that PD-L1 protein expression could serve as a biomarker for BCG-failure.

Methods

HR-NMIBC patients who received ≥ 5 BCG instillations were included. Tissue microarrays were constructed from BCG-naïve tumors and recurrences and stained with the PD-L1 (SP142) antibody. PD-L1 status was defined as ≥ 5% tumor-infiltrating immune cells with membrane staining in the tumor area. Clinicopathological associations with PD-L1 positive tumors were investigated, and time-to-event analyses were performed comparing PD-L1 positive vs. negative tumors.

Results

432 BCG-naïve tumors and 160 recurrences were included, and 91% of patients received adequate BCG. In BCG-naïve tumors, PD-L1 was expressed in 7% of patients and PD-L1 expression was associated with stage T1 versus Ta disease ( p = 0.015). PD-L1 expression was not associated with treatment failure after adequate BCG ( p = 0.782) nor with progression-free survival ( p = 0.732). Testing cut-offs of ≥ 1% and ≥ 10% PD-L1 positivity did not alter results. High PD-L1 expression was more frequent in tumor recurrences (14%) as compared to BCG-naïve tumors ( p = 0.012).

Conclusion

PD-L1 expression in HR-NMIBC is not a biomarker of response to BCG. However, PD-L1 is higher in a subset of tumors that failed BCG treatment. More research is needed to determine the role of PD-L1 in tumors where BCG treatment failed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsB7-H1 AntigenBCG VaccineBiomarkers, TumorNeoplasm InvasivenessHumansMaleFemaleAgedMiddle AgedAdjuvants, ImmunologicRetrospective StudiesRisk AssessmentAdministration, IntravesicalNeoplasm Recurrence, LocalTreatment OutcomeNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

BCGBladder cancerImmunotherapyPD-L1PrognosisProgressionRecurrence

Substanzen

B7-H1 AntigenBCG VaccineCD274 protein, humanBiomarkers, TumorAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, Room Be-304, 3015 GD, Rotterdam, The Netherlands.
  • Department of Pathology, Helse Stavanger HF, Stavanger, Norway.
  • Pathan BV, Department of Pathology, Rotterdam, The Netherlands.
  • Department of Pathology, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Urology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
  • Department of Urology, Amphia, Breda, The Netherlands.

Förderung

  • Erasmus Universitair Medisch Centrum Rotterdam

Zitieren

APA

de Jong, F. C., Kvikstad, V., Hoedemaeker, R. F., van der Made, A. C. J., van der Bosch, T. P., van Casteren, N. J., van Kessel, K. E. M., Zwarthoff, E. C., Boormans, J. L., & Zuiverloon, T. C. M. (2025). PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG. World Journal of Urology. https://doi.org/10.1007/s00345-024-05392-5

Vancouver

de Jong FC, Kvikstad V, Hoedemaeker RF, van der Made ACJ, van der Bosch TP, van Casteren NJ, et al. PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG. World Journal of Urology. 2025. doi:10.1007/s00345-024-05392-5

BibTeX
@article{deJong2025,
  author = {de Jong, Florus C and Kvikstad, Vebjørn and Hoedemaeker, Robert F and van der Made, Angelique C J and van der Bosch, Thierry P and van Casteren, Niels J and van Kessel, Kim E M and Zwarthoff, Ellen C and Boormans, Joost L and Zuiverloon, Tahlita C M},
  title = {PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG},
  journal = {World Journal of Urology},
  year = {2025},
  doi = {10.1007/s00345-024-05392-5}
}
Kostenlos starten →